Drug
Carfilzomib
Carfilzomib: highest development phase Phase 2, developed by Amgen, Bristol-Myers Squibb, United Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Amgen, Bristol-Myers Squibb, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Carfilzomib NCT02294357 | Phase 2 | Multiple Myeloma |
| Carfilzomib NCT03815279 | Phase 2 | Multiple Myeloma |
| Carfilzomib NCT03605719 | Phase 1 | Recurrent Plasma Cell Myeloma |
| carfilzomib NCT01738594 | Phase 1 | Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma |
Latest
No recent events.
Follow Carfilzomib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.